欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
Highlights of the DNA Vaccines 2011 Meeting
In July 2011, DNA vaccine researchers from the world over met once again to present and discuss their research at the 2011 DNA
Vaccine meeting held July 12–14 in beautiful San Diego, CA along scenic Coronado Bay. This meeting, presented under the auspices
of the International Society of DNA Vaccines, centered on the theme of “Building on Clinical Progress and Exploring New Targets”.
This provocative meeting covered studies on a number of important immunotherapy and vaccine targets, including those for
infectious agents as well as those for non-infectious diseases. A number of these studies are included in the special issue highlighting
the presentations made at this meeting. As well, we are very pleased to have the opportunity to present these papers in a peer-reviewed
Special Issue of the excellent journal Human Vaccines & Immunotherapeutics.
In this issue a number of important viral infectious agents are targeted, i.e., human immunodeficiency virus (HIV), cytomegalovirus
(CMV) and Ebola. Bacterial and parasitic agents also were targeted, as exemplified by the papers included in this issue on
Staphylococcus aureus and malaria, respectively. Likewise, several cancer immunotherapy papers targeting melanoma are highlighted.
There has also been a continued interest and effort in the field to utilize immune co-stimulatory molecules to further drive the
potential efficacy of DNA vaccines and immunotherapeutics. This is exemplified by papers in this issue using interleukin-12 (IL-12),
CCL25 chemokine, granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-28 (IL-28). Importantly, the use
of these immunomodulatory agents has been applied to infectious agents as well as cancer. Lastly, there has been a continued interest
and work in the area of applying “forcing” methods to assist the DNA to get into cells, with subsequent enhanced expression and
associated biological activity. This is exemplified by presentations that include the use of in vivo electroporation as well as more novel
delivery methods such as magneto-permeabilization and helium plasma, both of which are contact-independent modalities. All of
these studies, as well as the others presented at the conference, have the important role of further documenting and potentially validating
the clinical potential of the DNA plasmid vaccine and immunotherapy technology.
In sum, we look forward to welcoming you and your colleagues back to San Diego in December 2012 for the next DNA Vaccines
Meeting, which of note will occur 20 years after the first reports of the ability of genes expressed from naked DNA plasmids to
induce relevant immune responses against some important infectious agents. We hope that this meeting will again be a productive
and provocative venue with publication opportunities to further push the recent advancements of DNA plasmids in the vaccine and
immunotherapy arenas to their full clinical potential. San Diego, here we come again! Hope to see you all there!
2011年DNA疫苗会议的亮点 2011年7月12-14日,来自世界各地的DNA疫苗研究人员又举行了一次会议,在美丽的圣地亚哥,加利福尼亚州科罗纳多湾介绍和讨论他们的研究。本次会议由国际核酸疫苗协会赞助,主题是临床进展和探索新目标。 让人兴奋的是这次会议覆盖了许多重要的免疫治疗和疫苗的目标,包括对传染性病原以及那些为非传染性疾病。这些研究​​中的许多专题介绍,以特刊的形式来突出呈现。同时,我们很高兴能有机会来呈现这些文件,发表在同行评审优秀期刊Human Vaccines & Immunotherapeutics。 在特刊中涉及到了一系列重要的病毒传染性病原体,即HIV, CMV和Ebola。细菌和寄生虫也进行了有针对性的研究,例如金黄色葡萄球菌和疟疾。同样,有针对黑色素瘤的肿瘤免疫治疗的研究。 还有一个持续的兴趣和努力,即利用免疫共刺激分子,以进一步推动DNA疫苗的潜在疗效和免疫疗法。有研究使用白细胞介素12(IL-12),CCL25趋化因子,粒细胞-巨噬细胞集落刺激因子和白细胞介素28(IL-28)。更重要的是,这些免疫调节剂已被应用到传染性病原体以及癌症。最后,人们对应用“强制”方法协助DNA进入细胞的方法有持续的兴趣和研究,以及随后的表达增强和相关的生物活性。这个例子包括使用在体内电穿孔,以及更新颖的呈递方法,如磁-通透和氦等离子体,这两者都是接触独立的方式。所有这些研究结果以及其他在会议上提出的结果具有重要作用,进一步证明和验证DNA的质粒疫苗和免疫治疗技术的临床应用前景。 总之,我们期待着欢迎你和你的同事们回到圣地亚哥来参加2012年12月的下一次DNA疫苗会议,请关注首例用裸DNA质粒表达诱导相关的免疫反应针对一些重要的传染性病原体的报告后20年发生的事情。我们希望本次会议将再次成为富有成效和让人兴奋的场所,提供出版机会并进一步推动DNA质粒疫苗和免疫疗法,充分发挥其临床应用前景。圣地亚哥,在这里,我们来了!希望能看到你们都在那里! |